Ryan Dorin, MD
Urology · Farmington, CTNPI 1679718175
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Medtronic at 59.3% of the total. 2025 is the largest year on record at $7,189, more than ten times the $671 reported in 2019.
Across 121 payments — averaging $136.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Baxter Healthcare$1K
- EDAP Technomed Inc$647
- Covidien LP$539
- Procept Biorobotics Corporation$521
- Photocure Inc$467
- plus $3K from 27 others
Across 66 payments — averaging $1533.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$62K
- Covidien LP$40K
What the payments were for
- Consulting fees$9,89760%
- Speaking & faculty fees$4002%
- Travel & lodging$1,85711%
- Food & beverage$4,35726%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 31 | $9,834 |
| Baxter Healthcare | 5 | $1,306 |
| EDAP Technomed Inc | 1 | $647 |
| Covidien LP | 9 | $539 |
| Procept Biorobotics Corporation | 4 | $521 |
| Photocure Inc | 6 | $467 |
| Bard Peripheral Vascular, Inc. | 1 | $400 |
| Ferring Pharmaceuticals Inc. | 5 | $239 |
| Pfizer | 11 | $217 |
| Intuitive Surgical | 3 | $215 |
| Merck | 5 | $204 |
| Boston Scientific | 2 | $190 |
| Dendreon Pharmaceuticals LLC | 4 | $182 |
| Calyxo, Inc. | 2 | $161 |
| Histosonics, Inc. | 1 | $154 |
| Tempus AI, Inc | 2 | $153 |
| Davol Inc. | 2 | $149 |
| Johnson & Johnson | 2 | $144 |
| Urogen Pharma, Inc. | 4 | $116 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| Janssen Research & Development, LLC | 1 | $85 |
| Astellas Pharma US Inc | 3 | $76 |
| Astellas Pharma Global Development | 1 | $70 |
| Endo USA, Inc. | 2 | $66 |
| Tolmar Pharmaceuticals, Inc. | 1 | $61 |
| Bayer | 2 | $60 |
| KARL Storz Endoscopy-america | 1 | $53 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $47 |
| Immunitybio, Inc. | 1 | $33 |
| Acerus Pharmaceuticals Corporation | 1 | $23 |
| AbbVie | 1 | $22 |
| Teleflex LLC | 1 | $18 |
| Telix Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TISSEEL$1,238
- FOCAL ONE$647
- AQUABEAM SYSTEM$354
- Cysview$262
- CVAC Aspiration System$144
- Axonics$142
- RYBREVANT$125
- CARVYKTI$125
- PROVENGE$115
- ADSTILADRIN$104
How this compares
$16,569 in reported general payments places this provider in the 85th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 97 | $483,662 |
| XtandiEnzalutamide | 21 | $287,927 |
| Tamsulosin Hcl | 226 | $2,690 |
| Testosterone | 12 | $1,992 |
| Oxybutynin Chloride ErOxybutynin Chloride | 71 | $1,830 |
| Dutasteride | 22 | $1,120 |
| Finasteride | 96 | $913 |
| Testosterone Cypionate | 12 | $512 |
| Oxybutynin Chloride | 18 | $485 |
| Prednisone | 86 | $283 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $196 |
| Cephalexin | 38 | $140 |
| Doxazosin Mesylate | 13 | $98 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $87 |
| Levofloxacin | 14 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $76 | $287,92721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 urology providers in Connecticut.
Other urology in Farmington
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
- David CrawleyNew London$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.